-
1
-
-
45549083917
-
Treatment of relapsed acute myeloid leukaemia
-
18473961 10.2174/157488706776876445 1:CAS:528:DC%2BD28XkvFyqs7k%3D
-
Kell J (2006) Treatment of relapsed acute myeloid leukaemia. Rev Recent Clin Trials 1:103-111
-
(2006)
Rev Recent Clin Trials
, vol.1
, pp. 103-111
-
-
Kell, J.1
-
2
-
-
28444490353
-
Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group Experience (Abstract 546)
-
10.1182/blood-2005-04-1623
-
Rowe JM, Li X, Cassileth PA, Appelbaum FR, Schiffer CA, Wiernik PH, Litzow MR, Cripe LD, Lazarus HM, Paietta E, Dewald GW, Weinstein HJ, Ogden AK, Woods WG, Shep-herd L, Feusner JH, Bloomfield CD, Tallman MS (2005) Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group Experience (Abstract 546). Blood 106:162a
-
(2005)
Blood
, vol.106
-
-
Rowe, J.M.1
Li, X.2
Cassileth, P.A.3
Appelbaum, F.R.4
Schiffer, C.A.5
Wiernik, P.H.6
Litzow, M.R.7
Cripe, L.D.8
Lazarus, H.M.9
Paietta, E.10
Dewald, G.W.11
Weinstein, H.J.12
Ogden, A.K.13
Woods, W.G.14
Shep-Herd, L.15
Feusner, J.H.16
Bloomfield, C.D.17
Tallman, M.S.18
-
3
-
-
0028077347
-
A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial
-
7967730 1:STN:280:DyaK2M%2FlslaqsQ%3D%3D
-
Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA (1994) A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 8:1847-1853
-
(1994)
Leukemia
, vol.8
, pp. 1847-1853
-
-
Vogler, W.R.1
McCarley, D.L.2
Stagg, M.3
Bartolucci, A.A.4
Moore, J.5
Martelo, O.6
Omura, G.A.7
-
4
-
-
17344366634
-
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
-
9665189 10.1038/sj.leu.2401066 1:CAS:528:DyaK1cXkvVensLk%3D
-
Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049-1055
-
(1998)
Leukemia
, vol.12
, pp. 1049-1055
-
-
Kern, W.1
Aul, C.2
Maschmeyer, G.3
Schönrock-Nabulsi, R.4
Ludwig, W.D.5
Bartholomäus, A.6
Bettelheim, P.7
Wörmann, B.8
Büchner, T.9
Hiddemann, W.10
-
5
-
-
0032809362
-
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study
-
10475617 10.1016/S0145-2126(99)00087-9 1:CAS:528:DyaK1MXlvFSqu7k%3D
-
Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum FR (1999) A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 23:787-794
-
(1999)
Leuk Res
, vol.23
, pp. 787-794
-
-
Karanes, C.1
Kopecky, K.J.2
Head, D.R.3
Grever, M.R.4
Hynes, H.E.5
Kraut, E.H.6
Vial, R.H.7
Lichtin, A.8
Nand, S.9
Samlowski, W.E.10
Appelbaum, F.R.11
-
6
-
-
0036286493
-
FLAG-Ida regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high risk myeloid malignancies
-
12191567 10.1016/S0145-2126(02)00003-6
-
De la Rubia J, Regadera AI, Martin G, Cervera J, Sanz G, Martínez J, Jarque I, García I, Andreu R, Moscardó F, Jiménez C, Mollá S, Benlloch L, Sanz M (2002) FLAG-Ida regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high risk myeloid malignancies. Leuk Res 26:725-730
-
(2002)
Leuk Res
, vol.26
, pp. 725-730
-
-
De La Rubia, J.1
Regadera, A.I.2
Martin, G.3
Cervera, J.4
Sanz, G.5
Martínez, J.6
Jarque, I.7
García, I.8
Andreu, R.9
Moscardó, F.10
Jiménez, C.11
Mollá, S.12
Benlloch, L.13
Sanz, M.14
-
7
-
-
0038180704
-
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: Single-center experience
-
12707726 1:CAS:528:DC%2BD3sXjtVehsr4%3D
-
Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V (2003) FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 82:231-235
-
(2003)
Ann Hematol
, vol.82
, pp. 231-235
-
-
Pastore, D.1
Specchia, G.2
Carluccio, P.3
Liso, A.4
Mestice, A.5
Rizzi, R.6
Greco, G.7
Buquicchio, C.8
Liso, V.9
-
8
-
-
0025185703
-
High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: A prospective randomized study
-
2226729 10.1111/j.1600-0609.1990.tb00445.x 1:STN:280: DyaK3M%2FjtF2itw%3D%3D
-
Martiat P, Ghilain JM, Ferrant A, Doyen C, Delannoy A, Chatelain C, Bosly A, Michaux JL, Sokal G (1990) High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study. Eur J Haematol 45:164-167
-
(1990)
Eur J Haematol
, vol.45
, pp. 164-167
-
-
Martiat, P.1
Ghilain, J.M.2
Ferrant, A.3
Doyen, C.4
Delannoy, A.5
Chatelain, C.6
Bosly, A.7
Michaux, J.L.8
Sokal, G.9
-
9
-
-
0034016884
-
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML)
-
10663618 10.1007/s002770050005 1:CAS:528:DC%2BD3cXjt1eqsw%3D%3D
-
Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L, Hoelzer D (2000) Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). Ann Hematol 79:30-35
-
(2000)
Ann Hematol
, vol.79
, pp. 30-35
-
-
Ganser, A.1
Heil, G.2
Seipelt, G.3
Hofmann, W.4
Fischer, J.T.5
Langer, W.6
Brockhaus, W.7
Kolbe, K.8
Ittel, T.H.9
Brack, N.10
Fuhr, H.G.11
Knuth, P.12
Höffken, K.13
Bergmann, L.14
Hoelzer, D.15
-
10
-
-
67649158524
-
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia
-
10.3346/jkms.2009.24.3.498 1:CAS:528:DC%2BD1MXovFCitLg%3D
-
Lee SR, Yang DH, Ahn JS, Kim YK, Lee JJ, Choi YJ, Shin HJ, Chung JS, Cho YY, Chae YS, Kim JG, Sohn SK, Kim HJ (2009) The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. J Kor Med Sci 24:498-503
-
(2009)
J Kor Med Sci
, vol.24
, pp. 498-503
-
-
Lee, S.R.1
Yang, D.H.2
Ahn, J.S.3
Kim, Y.K.4
Lee, J.J.5
Choi, Y.J.6
Shin, H.J.7
Chung, J.S.8
Cho, Y.Y.9
Chae, Y.S.10
Kim, J.G.11
Sohn, S.K.12
Kim, H.J.13
-
11
-
-
0027534992
-
The management of recurrent acute myelogenous leukemia at a single center over a fifteen year period
-
7683485 10.1111/j.1365-2141.1993.tb04664.x 1:STN:280:DyaK3s3kvFyktg%3D%3D
-
Davis C, Rohatiner A, Amess J, Lim J, Lister TA (1993) The management of recurrent acute myelogenous leukemia at a single center over a fifteen year period. Br J Haematol 83:404-411
-
(1993)
Br J Haematol
, vol.83
, pp. 404-411
-
-
Davis, C.1
Rohatiner, A.2
Amess, J.3
Lim, J.4
Lister, T.A.5
-
12
-
-
9544254832
-
Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: A GIMEMA study of 218 unselected consecutive patients
-
Liso V, Iacopino P, Avvisati G, Petti MC, Broccia G, Carotenuto M, Falda M, Fazzi P, Lazzarino M, Leoni P, Mirto S, Pucci G, Nobile F, Nosari AM, Specchia G, Stasi R, Tabilio A, Mandelli F (1996) Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Leukemia 110:1443-1452
-
(1996)
Leukemia
, vol.110
, pp. 1443-1452
-
-
Liso, V.1
Iacopino, P.2
Avvisati, G.3
Petti, M.C.4
Broccia, G.5
Carotenuto, M.6
Falda, M.7
Fazzi, P.8
Lazzarino, M.9
Leoni, P.10
Mirto, S.11
Pucci, G.12
Nobile, F.13
Nosari, A.M.14
Specchia, G.15
Stasi, R.16
Tabilio, A.17
Mandelli, F.18
-
13
-
-
0030451886
-
Probability of long term disease free survival for acute myeloid leukemia patients after first relapse: A single center experience
-
9006744 10.1093/oxfordjournals.annonc.a010796 1:STN:280: DyaK2s7lvFCjtg%3D%3D
-
Vignetti M, Orsini E, Petti MC, Moleti MR, Andrizzi C, Pinto RM, Amdori S, Meloni G (1996) Probability of long term disease free survival for acute myeloid leukemia patients after first relapse: a single center experience. Ann Oncol 7:933-938
-
(1996)
Ann Oncol
, vol.7
, pp. 933-938
-
-
Vignetti, M.1
Orsini, E.2
Petti, M.C.3
Moleti, M.R.4
Andrizzi, C.5
Pinto, R.M.6
Amdori, S.7
Meloni, G.8
-
14
-
-
38049153331
-
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the Polish Adult Leukemia Group
-
Polish Adult Leukemia Group 18076637 10.1111/j.1600-0609.2007.00988.x 1:CAS:528:DC%2BD1cXivFahsbo%3D
-
Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-KuÅ A, Polish Adult Leukemia Group (2008) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 80:115-126
-
(2008)
Eur J Haematol
, vol.80
, pp. 115-126
-
-
Wierzbowska, A.1
Robak, T.2
Pluta, A.3
Wawrzyniak, E.4
Cebula, B.5
Hołowiecki, J.6
Kyrcz-Krzemień, S.7
Grosicki, S.8
Giebel, S.9
Skotnicki, A.B.10
Piatkowska-Jakubas, B.11
Kuliczkowski, K.12
Kiełbiński, M.13
Zawilska, K.14
Kłoczko, J.15
Wrzesień-Kuå, A.16
-
15
-
-
33748931318
-
IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: A single-center experience
-
16988532 10.1097/01.mjt.0000181690.21601.09
-
Yavuz S, Paydas S, Disel U, Sahin B (2006) IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther 13:389-393
-
(2006)
Am J Ther
, vol.13
, pp. 389-393
-
-
Yavuz, S.1
Paydas, S.2
Disel, U.3
Sahin, B.4
-
16
-
-
33746105303
-
Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia
-
16791270 10.1038/sj.leu.2404287 1:CAS:528:DC%2BD28XntVWksro%3D
-
Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL (2006) Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20:1361-1367
-
(2006)
Leukemia
, vol.20
, pp. 1361-1367
-
-
Jin, J.1
Jiang, D.Z.2
Mai, W.Y.3
Meng, H.T.4
Qian, W.B.5
Tong, H.Y.6
Huang, J.7
Mao, L.P.8
Tong, Y.9
Wang, L.10
Chen, Z.M.11
Xu, W.L.12
-
17
-
-
0022135739
-
Proposed revised criteria for the classification of acute myeloid leukemia
-
3862359 10.7326/0003-4819-103-4-620 1:STN:280:DyaL2MzgsFaitg%3D%3D
-
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620-625
-
(1985)
Ann Intern Med
, vol.103
, pp. 620-625
-
-
Bennett, J.M.1
Catovsky, D.2
Daniel, M.T.3
Flandrin, G.4
Galton, D.A.5
Gralnick, H.R.6
Sultan, C.7
-
18
-
-
0019979989
-
Cytosine arabinoside with daunorybicin or adriamycin therapy with acute myelocytic leukemia: A CALGB study
-
6953986 1:STN:280:DyaL383jt1Gmtw%3D%3D
-
Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF (1982) Cytosine arabinoside with daunorybicin or adriamycin therapy with acute myelocytic leukemia: a CALGB study. Blood 60:454-463
-
(1982)
Blood
, vol.60
, pp. 454-463
-
-
Yates, J.1
Glidewell, O.2
Wiernik, P.3
Cooper, M.R.4
Steinberg, D.5
Dosik, H.6
Levy, R.7
Hoagland, C.8
Henry, P.9
Gottlieb, A.10
Cornell, C.11
Berenberg, J.12
Hutchison, J.L.13
Raich, P.14
Nissen, N.15
Ellison, R.R.16
Frelick, R.17
James, G.W.18
Falkson, G.19
Silver, R.T.20
Haurani, F.21
Green, M.22
Henderson, E.23
Leone, L.24
Holland, J.F.25
more..
-
20
-
-
0024268774
-
Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro
-
3199844 10.1016/0145-2126(88)90039-2 1:CAS:528:DyaL1MXltVyqtg%3D%3D
-
Kong XB, Fanucchi MP, Chou TC (1988) Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D- arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. Leuk Res 12:853-859
-
(1988)
Leuk Res
, vol.12
, pp. 853-859
-
-
Kong, X.B.1
Fanucchi, M.P.2
Chou, T.C.3
-
21
-
-
0025023047
-
Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia
-
2401166 1:STN:280:DyaK3czot1WgtA%3D%3D
-
Bian SG, Hao YS, Wang ZC (1990) Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia. Chung Hua Nei Ko Tsa Chih 29:22-25
-
(1990)
Chung Hua Nei Ko Tsa Chih
, vol.29
, pp. 22-25
-
-
Bian, S.G.1
Hao, Y.S.2
Wang, Z.C.3
-
22
-
-
0019983219
-
Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside
-
6950658 1:STN:280:DyaL387ls1ChsA%3D%3D
-
Takahashi I, Hara M, Uchida K, Takaoka K, Watanabe S, Lai M, Hamasaki K, Kohi F, Kitajima K, Kimura I, Adachi T, Yorimitsu S, Tokioka M, Sanada H (1982) Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside. Acta Med Okayama 36:77-80
-
(1982)
Acta Med Okayama
, vol.36
, pp. 77-80
-
-
Takahashi, I.1
Hara, M.2
Uchida, K.3
Takaoka, K.4
Watanabe, S.5
Lai, M.6
Hamasaki, K.7
Kohi, F.8
Kitajima, K.9
Kimura, I.10
Adachi, T.11
Yorimitsu, S.12
Tokioka, M.13
Sanada, H.14
-
23
-
-
0032836387
-
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
-
10525830 10.1007/s002770050541 1:CAS:528:DyaK1MXlvFKmurk%3D
-
Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, Tesch H, Diehl V, Dias Wickramanayake P (1999) Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 78:418-425
-
(1999)
Ann Hematol
, vol.78
, pp. 418-425
-
-
Steinmetz, H.T.1
Schulz, A.2
Staib, P.3
Scheid, C.4
Glasmacher, A.5
Neufang, A.6
Franklin, J.7
Tesch, H.8
Diehl, V.9
Dias Wickramanayake, P.10
-
24
-
-
0035136931
-
A multicenter, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess of blasts in transformation
-
11167793 10.1046/j.1365-2141.2001.02551.x 1:CAS:528:DC%2BD3MXhtl2hsro%3D
-
Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP (2001) A multicenter, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess of blasts in transformation. Br J Haematol 112:127-137
-
(2001)
Br J Haematol
, vol.112
, pp. 127-137
-
-
Jackson, G.1
Taylor, P.2
Smith, G.M.3
Marcus, R.4
Smith, A.5
Chu, P.6
Littlewood, T.J.7
Duncombe, A.8
Hutchinson, M.9
Mehta, A.B.10
Johnson, S.A.11
Carey, P.12
Mackie, M.J.13
Ganly, P.S.14
Turner, G.E.15
Deane, M.16
Schey, S.17
Brookes, J.18
Tollerfield, S.M.19
Wilson, M.P.20
more..
-
25
-
-
0035760302
-
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study
-
11719356 10.1182/blood.V98.12.3212 1:CAS:528:DC%2BD3MXovVSgsrc%3D
-
List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212-3220
-
(2001)
Blood
, vol.98
, pp. 3212-3220
-
-
List, A.F.1
Kopecky, K.J.2
Willman, C.L.3
Head, D.R.4
Persons, D.L.5
Slovak, M.L.6
Dorr, R.7
Karanes, C.8
Hynes, H.E.9
Doroshow, J.H.10
Shurafa, M.11
Appelbaum, F.R.12
-
26
-
-
23944456658
-
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: A report of the Polish Adult Leukemia Group
-
Polish Adult Leukemia Group 15856358 10.1007/s00277-005-1046-0
-
Wrzesień-KuÅ A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Polish Adult Leukemia Group (2005) A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 84:557-564
-
(2005)
Ann Hematol
, vol.84
, pp. 557-564
-
-
Wrzesień-Kuå, A.1
Robak, T.2
Wierzbowska, A.3
Lech-Marańda, E.4
Pluta, A.5
Wawrzyniak, E.6
Krawczyńska, A.7
Kuliczkowski, K.8
Mazur, G.9
Kiebiński, M.10
Dmoszyńska, A.11
Wach, M.12
Hellmann, A.13
Baran, W.14
Hołowiecki, J.15
Kyrcz-Krzemień, S.16
Grosicki, S.17
-
27
-
-
12644313240
-
FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia
-
9003155 10.1007/s002770050239 1:CAS:528:DyaK2sXps1OgsA%3D%3D
-
Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jäger U, Knöbl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kalhs P, Haas OA, Lechner K (1996) FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73:265-271
-
(1996)
Ann Hematol
, vol.73
, pp. 265-271
-
-
Huhmann, I.M.1
Watzke, H.H.2
Geissler, K.3
Gisslinger, H.4
Jäger, U.5
Knöbl, P.6
Pabinger, I.7
Korninger, L.8
Mannhalter, C.9
Mitterbauer, G.10
Schwarzinger, I.11
Kalhs, P.12
Haas, O.A.13
Lechner, K.14
-
28
-
-
0032819748
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 Trial)
-
10450749 10.1038/sj.leu.2401474 1:CAS:528:DyaK1MXlvVOiurc%3D
-
Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E (1999) Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 13:1214-1220
-
(1999)
Leukemia
, vol.13
, pp. 1214-1220
-
-
Thomas, X.1
Fenaux, P.2
Dombret, H.3
Delair, S.4
Dreyfus, F.5
Tilly, H.6
Vekhoff, A.7
Cony-Makhoul, P.8
Leblond, V.9
Troussard, X.10
Cordonnier, C.11
De Revel, T.12
Simon, M.13
Nicolini, F.14
Stoppa, A.M.15
Janvier, M.16
Bordessoule, D.17
Rousselot, P.18
Ffrench, M.19
Marie, J.P.20
Archimbaud, E.21
more..
-
29
-
-
0034988112
-
Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial
-
UK MRC Adult Leukemia Working Party 11380463 10.1046/j.1365-2141.2001. 02785.x 1:STN:280:DC%2BD3M3pvVGgsQ%3D%3D
-
Liu Yin JA, Wheatley K, Rees JK, Burnett AK, UK MRC Adult Leukemia Working Party (2001) Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 113:713-726
-
(2001)
Br J Haematol
, vol.113
, pp. 713-726
-
-
Liu Yin, J.A.1
Wheatley, K.2
Rees, J.K.3
Burnett, A.K.4
-
30
-
-
10744221800
-
Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
-
14671635 10.1038/sj.leu.2403243 1:CAS:528:DC%2BD2cXlt1antg%3D%3D
-
Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G, Jäger U, Kainz B, Geissler K, Valent P, Sperr WR, Knöbl P, Schwarzinger I, Gleiss A, Lechner K (2004) Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 18:293-302
-
(2004)
Leukemia
, vol.18
, pp. 293-302
-
-
Weltermann, A.1
Fonatsch, C.2
Haas, O.A.3
Greinix, H.T.4
Kahls, P.5
Mitterbauer, G.6
Jäger, U.7
Kainz, B.8
Geissler, K.9
Valent, P.10
Sperr, W.R.11
Knöbl, P.12
Schwarzinger, I.13
Gleiss, A.14
Lechner, K.15
-
31
-
-
20244361887
-
Prognostic index for adult patients with acute myeloid leukemia in first relapse
-
15632409 10.1200/JCO.2005.06.027
-
Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Van der Lelie J, Boogaerts MA, Löwenberg B (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969-1978
-
(2005)
J Clin Oncol
, vol.23
, pp. 1969-1978
-
-
Breems, D.A.1
Van Putten, W.L.2
Huijgens, P.C.3
Ossenkoppele, G.J.4
Verhoef, G.E.5
Verdonck, L.F.6
Vellenga, E.7
De Greef, G.E.8
Jacky, E.9
Van Der Lelie, J.10
Boogaerts, M.A.11
Löwenberg, B.12
-
32
-
-
3943062139
-
Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia
-
15339685 1:CAS:528:DC%2BD2MXjsF2jsbo%3D
-
Ferrara F, Palmieri S, Mele G (2004) Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 89:998-1008
-
(2004)
Haematologica
, vol.89
, pp. 998-1008
-
-
Ferrara, F.1
Palmieri, S.2
Mele, G.3
-
33
-
-
0033975925
-
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities
-
for the German AML Cooperative Group 10673737 10.1038/sj.leu.2401668 1:STN:280:DC%2BD3c7jvFGnsw%3D%3D
-
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B, Buchner T, Hiddemann W, for the German AML Cooperative Group (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 14:226-231
-
(2000)
Leukemia
, vol.14
, pp. 226-231
-
-
Kern, W.1
Schoch, C.2
Haferlach, T.3
Braess, J.4
Unterhalt, M.5
Wormann, B.6
Buchner, T.7
Hiddemann, W.8
-
34
-
-
0034009065
-
Treatment of relapsed and refractory acute myelogenous leukemia
-
10720145 10.1038/sj.leu.2401568 1:CAS:528:DC%2BD3cXit1akt7w%3D
-
Estey E (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14:476-479
-
(2000)
Leukemia
, vol.14
, pp. 476-479
-
-
Estey, E.1
-
35
-
-
79958108730
-
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: A GOELAMS study
-
21331073 10.1038/leu.2011.25 1:STN:280:DC%2BC3MrosVWjuw%3D%3D
-
Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, Filanovsky K, Cornillet-Lefebvre P, Luquet I, Lode L, Richebourg S, Blanchet O, Gachard N, Vey N, Ifrah N, Milpied N, Harousseau JL, Bene MC, Mohty M, Delaunay J (2011) A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 25:939-944
-
(2011)
Leukemia
, vol.25
, pp. 939-944
-
-
Chevallier, P.1
Labopin, M.2
Turlure, P.3
Prebet, T.4
Pigneux, A.5
Hunault, M.6
Filanovsky, K.7
Cornillet-Lefebvre, P.8
Luquet, I.9
Lode, L.10
Richebourg, S.11
Blanchet, O.12
Gachard, N.13
Vey, N.14
Ifrah, N.15
Milpied, N.16
Harousseau, J.L.17
Bene, M.C.18
Mohty, M.19
Delaunay, J.20
more..
|